Cargando…

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report

Platinum-based chemotherapy is the standard chemotherapy for high grade serous ovarian cancer and primary peritoneal high-grade serous carcinoma. PARP inhibitors have changed the paradigm of the treatment in platinum-sensitive ovarian cancers and primary peritoneal high-grade serous carcinoma with B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buttitta, Fiamma, Di Marino, Pietro, Felicioni, Lara, Primavera, Francesca Chiara, Ferro, Benedetta, Zampacorta, Claudia, Pasciuto, Maria Paola, Rossetti, Rebecca, Tudini, Marianna, Marchetti, Antonio, D’Angelo, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pacini Editore srl 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462999/ https://www.ncbi.nlm.nih.gov/pubmed/37114628 http://dx.doi.org/10.32074/1591-951X-871

Ejemplares similares

POLE exonuclease domain mutations in endometrial carcinoma: a case report
por: Pasciuto, Maria Paola, et al.
Publicado: (2023)

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022)

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments
por: Marchetti, Antonio, et al.
Publicado: (2019)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Placental site trophoblastic tumor (PSTT): a case report and review of the literature
por: Zampacorta, Claudia, et al.
Publicado: (2023)

Mutational Profile of GNAQ (Q209) in Human Tumors
por: Lamba, Simona, et al.
Publicado: (2009)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer()()
por: Gasparini, Giampietro, et al.
Publicado: (2014)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
por: Marchetti, Antonio, et al.
Publicado: (2014)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
por: Buttitta, Fiamma, et al.
Publicado: (2020)

Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation
por: Chong, Gun Oh, et al.
Publicado: (2020)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2019)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
por: Walton, Josephine B., et al.
Publicado: (2017)

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
por: Mylavarapu, Sanghamitra, et al.
Publicado: (2018)

Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
por: Walton, Josephine B., et al.
Publicado: (2018)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas
por: Arias-Diaz, Andrea Estrella, et al.
Publicado: (2023)

Si-microstrip detector with intrinsic amplification
por: Govorkov, B B, et al.
Publicado: (1993)

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
por: Capoluongo, Ettore, et al.
Publicado: (2019)

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
por: Yu, Kun-Hsing, et al.
Publicado: (2020)

Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma
por: Conroy, Michael, et al.
Publicado: (2017)

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
por: Lazzaro, Carlo, et al.
Publicado: (2023)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
por: Kahramanoğlu, İlker, et al.
Publicado: (2018)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
por: Clarfield, Lauren, et al.
Publicado: (2022)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
por: Gasimli, Khayal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1vq9tbm5bp7ae7s1sp2h0319p7